KBC I really like that and I would be extremely happy with that scenario.

Keep in mind, from some very quick research I did on Feb 1, 2017 the search I did showed there were 2 companies involved in the development of enzalutimide (an androgen receptor inhibitor) ...Medivation (2004) and Astellas. A phase lll trial called AFFIRM started in Sept 2009. Enzalutimide resulted in an 89% reduction in PSA after 1 month of treatment. FDA approved the drug in Aug 2012. Medavation owned 50% of of enzalutimide and sold their portion to Pfizer for $14 billion in August of 2016.

So a couple of points. 

1. FDA approval seemed to come fairly quickly after the phase lll trial success.
2. Pfizer did not jump in until 4 years later.

While I am often very critical I am also very hopeful that zen3694 will show solid promise soon.

Anyway, this sounds like a Zenith post but it is only here as related to converging the 2 companies. I prefer them separate.

GLTA

Toinv